Faust changes name to Domain Therapeutics
This article was originally published in Scrip
Executive Summary
Faust Pharmaceuticals has changed its name to Domain Therapeutics to reflect its new business model and activities better. The company was previously focused on its G protein-coupled receptors (GCPR) technology to build its own pipeline, but will now give other companies involved in GCPR drug discovery access to this platform. Domain will explore other targets to concentrate on areas outside of central nervous system diseases. Domain hopes to raise funds and sign collaborations for its technology platformand build partnerships for its products.